drugset / Trial / NCT06452537
Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety and efficacy of Tocilizumab in MOGAD.
Timeline
- Start
- 2024-07-09
- Primary completion
- 2026-01-01
- Completion
- 2026-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Background | Prednisone | Other / unclassified | 7.5 mg | Oral |